Peripheral Neuropathy outcome measures standardization study (PERINOMS)
|Sponsor||Erasmus Medical Centre|
|CI||Dr M. Lunn|
|UK sites||London Queen square|
To expand the clinical knowledge on outcome measures. Also, the general applicability of an autonomic symptoms scale plus some selected activity limitation scales will be examined.
Outcome measures will be assessed in a cross-sectional and longitudinal group of patients.
Different levels of outcome in autoimmune polyneuropathies will be assessed:
- activity & participation limitation
- and quality of life
The ultimate goal of this study is the presentation of a specific minimum core set of outcome measures.
These could be used in future clinical and follow-up studies in patients with polyneuropathy, mainly those patients with autoimmune mediated polyneuropathies.
Collaboration with several local, European, and USA neurological centres. All with great experience in dealing with inflammatory neurological disorders.
Patients with polyneuropathies, particularly
- Guillain-Barre Syndrome (GBS)
- Chronic Inflammatory Demyelinaing Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN)
- and autoimmune small fibre neuropathies (AI-SFN).